A Phase 4 clinical trial evaluating semaglutide was marked as completed on August 3, 2026. The study, registered as NCT05548647 and titled "Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects," examined long-term effects related to appetite and eating behavior.
The trial's status was updated to COMPLETED as of the listed date, according to its ClinicalTrials.gov record. No results or outcome data were included in this update. The record confirms the study phase as Phase 4, indicating research conducted after regulatory approval of the compound.
Semaglutide remains an approved medication, and this trial update reflects only the completion status of the study, not any findings or conclusions about the drug's effects. Further details, including any eventual results, may be published separately on the trial's official registry page.
Readers interested in background information on semaglutide, including its approved uses and general profile, can consult the compound overview for additional context.